Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure

Alric, Laurent; Leroy, Vincent; Radenne, Sylvie; Vallet-Pichard, Anaïs; Dumortier, Jérôme; Bailly, François; Pageaux, Georges-Philippe; Habersetzer, François; Grange, Jean-Didier; Gagnieu, Marie-Claude; Minello, Anne; Guillaud, Olivier; Kamar, Nassim

doi:10.1093/ndt/gfw348

Record: found
Abstract: not found
Article: not found

Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure

Author(s): Jérôme Dumortier , François Bailly , Georges-Philippe Pageaux , Anaïs Vallet-Pichard , Sylvie Radenne , François Habersetzer , Marie-Claude Gagnieu , Jean-Didier Grangé , Anne Minello , Olivier Guillaud , Nassim Kamar , Laurent Alric , Vincent Leroy

Publication date (Electronic): October 19 2016

Journal: Nephrology Dialysis Transplantation

Publisher: Oxford University Press (OUP)

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Chronic hepatitis C virus (HCV) infection is the most common chronic liver disease in patients with end-stage renal disease (ESRD). Over the last few years, second-generation direct-acting antivirals have been revolutionary in the treatment of hepatitis C, and sofosbuvir (SOF) is the backbone of most modern treatment strategies. Since SOF is eliminated through the kidney, the aim of this multicentre retrospective study was to assess its antiviral efficacy and safety in HCV-infected patients with severe renal failure [including haemodialysis (HD) patients].

Related collections

Most cited references 30

Record: found
Abstract: found
Article: not found

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.

David Roth, David R. Nelson, Annette Bruchfeld … (2015)

Chronic hepatitis C virus (HCV) infection in patients with stage 4-5 chronic kidney disease increases the risk of death and renal graft failure, yet patients with hepatitis C and chronic kidney disease have few treatment options. This study assesses an all-oral, ribavirin-free regimen in patients with HCV genotype 1 infection and stage 4-5 chronic kidney disease.

0 comments Cited 185 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.

Varun Saxena, Farrukh Koraishy, Meghan E. Sise … (2016)

Renal clearance is the major elimination pathway for sofosbuvir (SOF). We assessed the safety and efficacy of SOF-containing regimens in patients with varying baseline estimated glomerular filtration rate (eGFR).

0 comments Cited 78 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.

Paul Pockros, K Rajender Reddy, Parvez Mantry … (2016)

Although hepatitis C virus (HCV) infection is common in patients with end-stage renal disease, highly efficacious, well-tolerated, direct-acting antiviral regimens have not been extensively studied in this population. We investigated the safety and efficacy of ombitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir (with or without ribavirin) in a prospective study of patients with stage 4 or 5 chronic kidney disease (CKD).